FOLFOX4与FLP方案治疗晚期胃癌的疗效比较  

Therapeutic outcomes of FOLFOX4 regimen versus FLP regimen for advanced gastric cancer

作　　者：余嘉文[1] 

机构地区：[1]安庆市石化医院肿瘤科,246001

出　　处：《中国现代药物应用》2013年第8期13-14,共2页Chinese Journal of Modern Drug Application

摘　　要：目的比较奥沙利铂(L-OHP)联合5-氟尿嘧啶(5-Fu)、亚叶酸钙(CF)(FOLFOX4)与顺铂(DDP)联合5-氟尿嘧啶、亚叶酸钙(CF)(FLP)方案治疗晚期胃癌的疗效及不良反应。方法全组55例,随机分为两组,FOLFOX4方案一线治疗27例,FLP方案28例。所有病例至少接受3周期治疗。结论 FOLFOX4组与FLP组比较,有效率44.4%和32.1%,中位TTP6.4个月和5.3个月(P<0.05),中位OS10.6个月和8.0个月。FOLFOX4组消化道反应和骨髓抑制较FLP组低,差异有统计学意义(P<0.05)。FOLFOX4组外周感觉神经毒性多为Ⅰ、Ⅱ度。结论 FOLFOX4与FLP方案比较在近期疗效上差异无统计学意义,但FOLFOX4方案毒副作用较轻,化疗时间短,对机体损伤小。Objective To compare the efficacy and toxicity between oxaliplatin plus 5-finorouracil and leucovorin （FOLFOX4） and combined cisplatin with 5-finorouracil and leucovorin （FLP） in the treatment of advanced gastric cancer Methods 55 patients with advanced gastric cancer were allocated two groups. One group （ n = 27 ）, received FOLFOX4 regimen as first-line chemotherapy and another（ n = 28 ） were given FLP regimen. All patients received three cycles of chemotherapy at least. Results The totle effective rate was 44. 4% （ FOLFOX4） VS 32. 1% （FLP） and the the median time to progression（mTYP） was 6. 4 months for patients with FOLFOX4 regimen and 5.3 months for those with FLP （ P 〈 0. 05 ）. The median overall survival （mOS） was 10. 6 months in FOLFOX4 group and 8. 0 months in FLP group. The incidence ofgastrointestinal rection and bone marrow suppression in FOLFOX4 group were lower than the FLP group, there was significant difference between the two groups（P 〈0. 05）. Neurotoxicity in the group FOLFOX4 was mostly grade Ⅰ and Ⅱ. Conclusion The difference in response rate was not statistical significant between the two groups, but the program FOLFOX4 had less side effects with short chemotherapy time and less damage to body.

关 键 词：奥沙利铂 氟尿嘧啶 顺铂 胃癌 化疗 

分 类 号：R735.2[医药卫生—肿瘤]